Matra Petroleum has been approved for listing on Nasdaq

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
74
Matra Petroleum has been approved for listing on Nasdaq First North and publishes company description

Matra Petroleum AB (publ) ("Matra Petroleum" or the "Company") has been approved for listing on Nasdaq First North. Trading in Matra Petroleum's shares is planned to commence on 20 April 2017 under the ticker symbol "MATRA". In connection to the listing of the Company shares on Nasdaq First North the Company has prepared a company description (the "Company Description") which as of today is available on Matra Petroleum's website, www.matrapetroleum.com and on Mangold Fondkommission's website www.mangold.se .

The listing on Nasdaq First North Matra Petroleum believes that the significant decline in the crude oil and gas prices between 2014 and 2016, opens up opportunities for companies with access to capital to acquire and develop low-risk producing oil and gas assets with attractive risk/return characteristics. Matra Petroleum considers that the listing will offer the Company and its shareholders a number of benefits, including:

  • Support for the Company's objective to develop and acquire producing oil and gas properties going forward;
  • Enhancing the profile of Matra Petroleum's business and status with existing and potential business partners;
  • Improved access to the capital market and liquidity for the Company's shareholders; and
  • Increased flexibility in reviewing and capitalizing on growth opportunities.

Background Earlier in 2017, Matra Petroleum broadened its Swedish shareholder base through a private placement directed to qualified investors and a public offering. In total the Company raised SEK 48.5 million at SEK 10 per share representing a pre-money valuation of SEK 370 million and a fully diluted post money valuation of SEK 415 million.

The Company's CEO Maxim Barskiy is the main shareholder controlling approximately 63% of the Company's shares through companies. The Company's chairman Eric Forss, privately and through company, holds approximately 5% of the shares

Advisors Mangold Fondkommission AB has acted as financial advisor to the Company in connection with the compilation of the Company Description. Baker McKenzie Advokatbyrå has acted as legal advisor to the Company in connection with the listing in respect of Swedish law.

Certified Adviser Mangold Fondkommission AB is the Company's Certified Adviser. Phone: +46 (0) 85 03 01 550 E-mail: info@mangold.se

For more information, please contact: Eric Forss , Chairman, Matra Petroleum AB Phone number: +46 8 611 49 95

Investor Relations Email: IR@matrapetroleum.com

This information is information that Matra Petroleum AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 11 April, 2017, at 14:45 CET.

About Matra Petroleum Matra is an independent oil and gas exploration and production company operating in the United States where the Company owns and operates 136 leases located in the Texas Panhandle region through its fully owned subsidiary Matra Petroleum Inc. ("Matra USA"). Matra USA was formed in 2013 through a series of mergers and acquisitions in the Texas Panhandle region. Since then, Matra USA has been producing and selling oil and gas in the same area. The Company has grown rapidly and currently owns 38,800 net acres in the Texas Panhandle region with a current daily production of 900 BOEPD and proven net reserves of 22.9 MMboe. Revenues from oil and gas operations amounted to USD 5.7 million (2015: USD 5.5 million) in 2016 and USD 2.0 million in the fourth quarter 2016 (q4 2015: USD 1.1 million).

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...ea388615b9

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading